Therapy Areas: Cardiovascular
Vifor Pharma Names Jensen as New Chief Medical Officer
13 September 2019 - - Swiss pharmaceutical group Vifor Pharma has hired Dr Klaus Henning Jensen as chief medical officer and Member of the executive committee in January 2020, the company said.
...
Dr. Reddy's Laboratories Launches Fosaprepitant for Injection in the US Market
13 September 2019 - - Indian pharmaceutical company Dr. Reddy's Laboratories Ltd. (BSE: 500124) (NSE: DRREDDY) (NYSE: RDY) has launched Fosaprepitant for Injection, the therapeutic generic equiva...
Alexion, BridgeBio Ink Japanese License Agreement for Eidos' Transthyretin Amyloidosis Investigational Medicine
12 September 2019 - - US-based drugmaker Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) and BridgeBio Pharma, Inc.'s (NASDAQ: BBIO) subsidiary Eidos Therapeutics, Inc. (NASDAQ: ...
Alnylam Presents New Clinical Research Findings at the Second European Meeting of ATTR Amyloidosis for Doctors and Patients
6 September 2019 - - US-based RNAi therapeutics company Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) shared new findings at the Second European Meeting of ATTR Amyloidosis (EU-ATTR) for Doctors a...
Northwest Biotherapeutics names new vice president, medical affairs & external collaborations
5 September 2019 - Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax personalised immune therapies for solid tumour cancers, announced yesterday th...
Detailed Results from Phase III DAPA-HF Trial Showed Farxiga Significantly Reduced Both the Incidence of Cardiovascular Death and the Worsening of Heart Failure
3 September 2019 - - British-Swedish drugmaker AstraZeneca has released detailed results from the landmark Phase III DAPA-HF trial that showed Farxiga (dapagliflozin) on top of standard of care reduce...